Clinical Trial Update: Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ALX-0081 to a GPIIb/IIIa inhibitor in high-risk PCI patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-st-segment Elevation Myocardial Infarction
• Stable Angina
• Unstable Angina

Drugs mentioned

• ALX-0081 (ALX-0081)
• GPIIb/IIIa inhibitor (GPIIb/IIIa inhibitor)

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI) | Phase 2 | Status: COMPLETED